Baumann BC, Mitra N, Harton JG, Xiao Y, Wojcieszynski AP, Gabriel PE, Zhong H, Geng H, Doucette A, Wei J, O’Dwyer PJ, Bekelman JE, Metz JM. Comparative effectiveness of proton therapy versus photon therapy as part of concurrent chemo-radiotherapy for locally advanced cancer. American Society of Clinical Oncology poster session. June 1, 2019.

Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base: First Long-Term Report. Read More

A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with imrt versus proton radiation therapy. Read More

Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. Read More

Proton Therapy Is Associated with Superior Survival and Decreased Risk of Complications Compared to IMRT for Intermediate Risk Prostate Cancer: A Medicare/SEER Database Study.

Bryant Survey Results.

Dose–Volume Comparison of Proton Therapy and Intensity-Modulated Radiotherapy for Prostate Cancer. Read More

Proton Therapy Is Associated with Superior Survival and Decreased Risk of Complications Compared to IMRT for Intermediate Risk Prostate Cancer: A Medicare/SEER Database Study.

Comparative Effectiveness Study of Patient-Reported Outcomes following Proton Therapy or IMRT for Prostate Cancer. Read More

Comparative toxicity and cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. Read More

Phase III randomized trial proton vs photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RADCOMP) Consortium trial.

Early Toxicity in Patients Treated With Postoperative Proton Therapy for Locally Advanced Breast Cancer. Read More

Partial Breast Radiation Therapy With Proton Beam: 5-Year Results With Cosmetic Outcomes. Read More

National Cancer Database Analysis of Proton Versus Photon Radiaion Therapy in NSCLC. Read More

Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung CancerFinal Results of a Phase 2 Study. Read More

High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Fractionation 10 for PBT vs 6-8 weeks for IMRT. Read More

Gastrostomy Tubes Decrease by Over 50% With Intensity Modulated Proton Therapy (IMPT) During the Treatment of Oropharyngeal Cancer Patients. Read More

Intensity Modulated Proton Therapy Versus Intensity Modulated Photon RT for Oropharyngeal Cancer: First Comparative Results of Patient Reported Outcomes. Read More

Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of IMPT and IMRT. Read More

Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Read More

Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Read More

Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus IMRT for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Read More

A Multi-Institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. Read More

Lymphocyte-sparing Effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation. Read More

Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Read More

Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Read More

Multi-Institutional Phase II Study of High Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Read More